CN104004059B - 一种关于白介素-33抑制剂多肽及其应用 - Google Patents
一种关于白介素-33抑制剂多肽及其应用 Download PDFInfo
- Publication number
- CN104004059B CN104004059B CN201410281926.2A CN201410281926A CN104004059B CN 104004059 B CN104004059 B CN 104004059B CN 201410281926 A CN201410281926 A CN 201410281926A CN 104004059 B CN104004059 B CN 104004059B
- Authority
- CN
- China
- Prior art keywords
- interleukin
- polypeptide
- cell
- pancreas
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 42
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 41
- 108010067003 Interleukin-33 Proteins 0.000 title claims abstract description 37
- 102000017761 Interleukin-33 Human genes 0.000 title claims abstract description 37
- 239000003112 inhibitor Substances 0.000 title claims description 23
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 21
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 21
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 21
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003560 cancer drug Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 abstract description 18
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- 230000005012 migration Effects 0.000 abstract description 6
- 238000013508 migration Methods 0.000 abstract description 6
- 230000004083 survival effect Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 34
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010033649 Pancreatitis chronic Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000015031 pancreas development Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410281926.2A CN104004059B (zh) | 2014-06-23 | 2014-06-23 | 一种关于白介素-33抑制剂多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410281926.2A CN104004059B (zh) | 2014-06-23 | 2014-06-23 | 一种关于白介素-33抑制剂多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104004059A CN104004059A (zh) | 2014-08-27 |
CN104004059B true CN104004059B (zh) | 2016-03-30 |
Family
ID=51364987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410281926.2A Active CN104004059B (zh) | 2014-06-23 | 2014-06-23 | 一种关于白介素-33抑制剂多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104004059B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096273A1 (en) * | 2003-04-28 | 2004-11-11 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating interleukin-6 related diseases |
WO2004022718A3 (en) * | 2002-09-06 | 2005-12-01 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
CN1822851A (zh) * | 2003-05-15 | 2006-08-23 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
CN102146413A (zh) * | 2011-01-17 | 2011-08-10 | 中国科学院广州生物医药与健康研究院 | 一种人重组白介素-3的表达纯化方法 |
-
2014
- 2014-06-23 CN CN201410281926.2A patent/CN104004059B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022718A3 (en) * | 2002-09-06 | 2005-12-01 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
WO2004096273A1 (en) * | 2003-04-28 | 2004-11-11 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating interleukin-6 related diseases |
CN1822851A (zh) * | 2003-05-15 | 2006-08-23 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
CN102146413A (zh) * | 2011-01-17 | 2011-08-10 | 中国科学院广州生物医药与健康研究院 | 一种人重组白介素-3的表达纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104004059A (zh) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ma et al. | Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis | |
Li et al. | Effectively suppressed angiogenesis-mediated retinoblastoma growth using celastrol nanomicelles | |
CN105056250B (zh) | 一种microRNA在制备治疗前列腺癌的药物中的应用 | |
CN107419004A (zh) | lncRNA‑RP11‑290F20.3及其小干扰RNA的应用 | |
Li et al. | TES inhibits colorectal cancer progression through activation of p38 | |
CN104004059B (zh) | 一种关于白介素-33抑制剂多肽及其应用 | |
CN109966479A (zh) | Ezh2在制备预防或治疗多囊肾病药物中的应用 | |
CN106955292B (zh) | 一种治疗食管癌的药物组合物及用途 | |
CN116650474A (zh) | 苍耳亭的医药新用途 | |
CN115990191A (zh) | 一种抗肿瘤的药物组合物 | |
CN104031128B (zh) | 一种白介素-33抑制剂多肽及其应用 | |
CN109833321A (zh) | 一种逆转肝癌细胞对sorafenib耐药性的药物组合物 | |
CN104004062B (zh) | 关于per2蛋白激动剂多肽及其应用 | |
CN104004056B (zh) | 一种关于Cyclin D蛋白抑制剂多肽及其应用 | |
CN109172557B (zh) | Ppm-18通过激活细胞内活性氧诱导膀胱癌细胞凋亡的应用 | |
CN104004061B (zh) | 白介素-33抑制剂多肽及其应用 | |
CN104017051B (zh) | 一种Cyclin D 蛋白抑制剂多肽及其应用 | |
CN1762346A (zh) | 雷公藤甲素在制备抗卵巢癌药物中的应用 | |
CN104086630B (zh) | 一种生长抑素受体激动剂多肽及其应用 | |
CN104004058B (zh) | 有关白介素-33抑制剂多肽及其应用 | |
CN103602625B (zh) | 含有重组腺病毒质粒的大肠杆菌及重组腺病毒的应用 | |
CN104045689B (zh) | 一种关于生长抑素受体激动剂多肽及其应用 | |
CN104045690B (zh) | 生长抑素受体激动剂多肽及其应用 | |
CN111407758A (zh) | 斑蝥素作为miR-214-3p/Wnt/β-Catenin信号通路抑制剂防治骨肉瘤的用途 | |
CN104004063B (zh) | 一种关于Npas2蛋白激动剂多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhou Yue Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160226 Address after: 222000 No. 160 Chaoyang Middle Road, Jiangsu, Lianyungang Applicant after: Zhou Yue Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: Suzhou Pu Luo Da Biotechnology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200826 Address after: 211100 floor 3, building B, Ruihong Biotechnology Park, 2289 Tianyuan East Road, Jiangning District, Nanjing City, Jiangsu Province Patentee after: Nanjing NANYAO Pharmaceutical Technology Co.,Ltd. Address before: 222000 No. 160 Chaoyang Middle Road, Jiangsu, Lianyungang Patentee before: Zhou Yue |
|
TR01 | Transfer of patent right |